Small Interfering RNA Therapeutics Market

Small Interfering RNA Therapeutics Market Size Survey Report – In a Glance

As per the survey report on global Small interfering RNA therapeutics market, the market is projected to foresee a CAGR of CAGR value 14.3 % between 2024-2033, and further generate a market size of USD 7.1 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 2.1 billion revenue.

• The global Small interfering RNA therapeutics market is projected to grow on account of the rising demand for targeted medicines.
• In Japan, the Small interfering RNA therapeutics market growth can be attributed to the rising acceptance of RNA therapeutics.
• KDMI analyst’s growth analysis foresees low knowledge of RNA-based medicines to challenge the market growth.
• North America, having the highest market share in the Small interfering RNA therapeutics market, is projected to dominate the global market.

Small Interfering RNA Therapeutics Market Analysis

Small interfering RNA (siRNA), also known as silencing RNA is a type of RNA molecule that can regulate the expression of genes by a biological phenomenon called RNA interference (RNAi) where it silences specific genes. In addition, siRNA therapeutics is an innovative and advanced approach to treat diseases by making use of siRNA to suppress or inhibit the expression of disease-causing genes specifically. This RNA based therapeutics is in fact a potential alternative option for the diseases which are not easily treatable.

The rising demand for targeted medicines is pushing the small-interfering RNA therapeutics market forward. As per the European Medicine Agency (EMA), 77 medicines are approved for commercialization, 39 of which have a new active substance and many represent impressive progress in their therapeutic areas, in 2023. Sanofi Genzyme, Genecon Biotechnologies Co. Ltd., Arbutus Biopharma Corp. are some of the significant parties in the global market for Small interfering RNA therapeutics.

Analyst’s Observation on Japan Small Interfering RNA Therapeutics Market Survey

In Japan, the market growth for Small interfering RNA therapeutics can be attributed to the rising acceptance of RNA therapeutics. Japan has recently made excellent progress in the acceptance and incorporation of RNA-based treatment technologies. The American Society of Gene + Cell Therapy stated that 31 gene therapies including genetically modified cell therapies, 30 RNA therapies, and 68 non-genetically modified cell therapies have been sanctioned across the globe, for clinical use. Also, 2,068 gene therapies (including genetically modified cell therapies such as CAR-T cell therapies) are being developed, consisting of 51% of gene, cell, and RNA therapies; 901 non-genetically modified cell therapies are being formulated, consisting of 22% of gene, cell, and RNA therapies.

Silence therapeutics AG, GalaxoSmithKline, Novartis are some of the significant parties in the market for Small interfering RNA therapeutics in Japan.

Small Interfering RNA Therapeutics Market Growth Driver and Challenges

Growth Driver

Increasing prevalence of cancer:

One of the dominant factors driving the growth of the global small interfering RNA (siRNA) therapeutics market is the mounting prevalence of cancer and infectious diseases. In modern times, genomic advancements and their accelerated growth are drastically transforming the field of biomedical science and medicine. Many new developments and innovations are unlocking the clinical potential that can targetedly modify the disease-causing gene expression. RNA-based drugs, including antisense oligonucleotides and short-interfering RNAs, are remarkably promising examples of this newer class of biologics. The report states that as indicated by the World Health Organization, about 9.6 million people succumbed to death in 2018 and its second-most reason for death is cancer. Furthermore, there is 1 death out of 6 individuals due to cancer, across the planet.

Restraint

Low knowledge of RNA-based medicines:

RNA-based medicines are used to direct cellular activities for producing specific proteins that can treat or prevent specific diseases. However, limited understanding and minimal awareness of RNA-based medicines and personalized medicines among the public is a major barrier to the growth of the small-interfering RNA therapeutics market. However, the low knowledge among the population can be due to various reasons like the pioneering technology and the complexity of the subject.

Small Interfering RNA Therapeutics Market Segmentation

Our experts at KD Market Insights have segmented the global Small interfering RNA therapeutics market research report as:

Small Interfering RNA Therapeutics Market Regional Synopsis

The North American small interfering RNA therapeutics market is majorly driven by the expanding substantial investments in biotechnology and pharmaceuticals, as well as a well-established healthcare framework. Due to the region’s major academic and research facilities, innovation and clinical trials in siRNA therapeutics are boosted. In addition, the surging awareness of genetic illnesses and the need for personalized medicine is leading the market in North America in which the United States takes the lead in the adoption of RNA-based therapeutics. It is also anticipated to be responsible for the dominant share of 37% by 2037 spurred by the increasing outlay in healthcare. Furthermore, in 2021, healthcare expenditure in the United States was fueled by more than 2%, to roughly USD 4 trillion, according to calculations.

Europe is foreseen to develop at the fastest CAGR and a lucrative growth of the global small interfering RNA (siRNA) therapeutics market during the forecast period. The region enjoys the advantage of the well-established system that encourages the discovery of novel therapeutics, and also an intensified focus on personalized medicine. Higher expenditures in research & development, along with the rising prevalence of genetic disorders also act as a driving force behind the growth of the market. Moreover, collaboration between pharmaceutical businesses with research institutions in Europe further strengthens the new siRNA technologies, boosting the siRNA therapeutics market growth.

As per our analysts at KD Market Insights, the following five players lead the North America Small interfering RNA therapeutics market growth:

• Novartis
• Novo Nordisk
• Quark Pharmaceuticals
• Dicerna Pharmaceuticals
• Sanofi Genzyme

Small Interfering RNA Therapeutics Market Competitive Landscape

Some of the key players who top the global Small interfering RNA therapeutics market share:

• GE Dharmacon
• OPKO Health, Inc.
• Alnylam Pharmaceuticals
• Arrowhead Research Corp
• Sanofi Genzyme
• Genecon Biotechnologies Co. Ltd.
• Arbutus Biopharma Corp
• Silence Therapeutics AG
• Sylentis S.A.
• Olix Pharmaceuticals
• GlaxoSmithKline
• Isis Pharmaceuticals/ Ionis Pharmaceuticals
• BenitecBiopharma Ltd.
• Bio-Path Holdings Inc.
• Calando Pharmaceuticals

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Small Interfering RNA Therapeutics Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Type
      2. By End-user
      3. By Indication
      4. By Region
5. Market Segmentation by Type
   1. 1. Liposome based systemic therapy
      2. Nanoparticle based systemic therapy
6. Market Segmentation by End-user
   1. 1. Hospitals
      2. Research institutions
      3. Pharmaceutical and biotechnology companies
      4. Academic institutions
7. Market Segmentation by Indication
   1. 1. Cardiovascular diseases
      2. Respiratory diseases
      3. Oncology
      4. Neurodegenerative diseases
      5. Infectious diseases
8. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
      3. Market Analysis by Type, End-user, and Indication
      4. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
   2. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      2. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      3. France
         1. Market Size and Forecast
         2. Key Trends and Developments
      4. Market Analysis by Type, End-user, and Indication
      5. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
      6. Market Analysis by Type, End-user, and Indication
      7. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      8. Rest of Europe
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
   3. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      2. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
      3. Market Analysis by Type, End-user, and Indication
      4. India
         1. Market Size and Forecast
         2. Key Trends and Developments
      5. Market Analysis by Type, End-user, and Indication
      6. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication

1. 1. 1. 1. South Korea
         2. Market Size and Forecast
         3. Key Trends and Developments
      2. Market Analysis by Type, End-user, and Indication
      3. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
   2. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
      2. Market Analysis by Type, End-user, and Indication Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      3. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      4. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
   3. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      2. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
      3. Market Analysis by Type, End-user, and Indication
      4. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Type, End-user, and Indication
      5. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
2. Market Analysis by Type, End-user, and Indication
3. Competitive Landscape
   1. Market Share Analysis
   2. Company Profiles
   3. Medtronic (Ireland)
   4. IBM
   5. Apple Inc.
   6. Siemens Medical Solutions
   7. Pepperl+Fuchs
   8. Cisco
   9. GE Healthcare
4. Strategic Recommendations
5. Appendix
   1. List of Tables
   2. List of Figures
6. References